Immunotherapy before surgery for localized melanoma
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests if giving two immunotherapy drugs (nivolumab and ipilimumab) before surgery can improve outcomes for patients with stage III melanoma that can be removed. It is for people who have not had certain treatments recently or whose melanoma is not in the eye.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You must have stage III melanoma that can be surgically removed and is measurable on scans
- Your melanoma must be in the skin or mucous membranes (not in the eye)
- If you have had prior anti-PD-1 immunotherapy, it must have stopped more than 6 months ago
- If you have had prior targeted therapy, it must have stopped more than 3 months ago
- You must not have melanoma that has spread to other parts of the body (distant metastases)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three immunotherapy drugs (ipilimumab, relatlimab, and nivolumab) given before surgery to people with melanoma that can be completely removed. The goal is to see if this treatment shrinks the tumor and improves outcomes.
This trial tests whether a combination of two immunotherapy drugs (nivolumab and relatlimab) can clear tiny amounts of cancer cells that remain after surgery in people with high-risk melanoma. It aims to prevent the cancer from coming back.
This trial is for people with stage III melanoma that can be surgically removed. It compares one immunotherapy drug to a combination of two, to see which works better before surgery.
This trial tests whether giving immunotherapy (anti-PD1) before and after surgery can help treat melanoma that has spread to nearby lymph nodes or skin. It is for people whose melanoma can be removed surgically, and who either haven't had systemic treatment before or whose melanoma has returned after prior immunotherapy or targeted therapy.
This trial tests two immunotherapy drugs, ipilimumab and nivolumab, given before surgery for people whose melanoma has come back after previous anti-PD1 treatment. The goal is to see if this combination can shrink the tumor and help prevent future recurrence.
This trial tests whether giving immunotherapy before surgery and possibly skipping some after may help people with advanced but removable melanoma. It aims to see if this approach can reduce the chance of the cancer coming back.
Hear when a new Cutaneous Melanoma, Stage III trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.